---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041597"
form_type: "8-K"
ticker: "ITRMF"
cik: "0001659323"
company_name: "Iterum Therapeutics plc"
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T14:42:06.206292+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Iterum Therapeutics Q2 net loss $12.2M; REASSURE trial 50% enrolled, topline data expected Q2 2024

## Summary
- Net loss $12.2M in Q2 2023 vs $6.7M in Q2 2022; non-GAAP net loss $10.0M.
- R&D expense $9.0M (up from $4.0M) driven by REASSURE trial costs; G&A $1.9M (down from $4.1M).
- Cash and short-term investments $44.7M; cash runway into Q3 2024.
- REASSURE trial: 50% enrollment (target 1,966 patients); enrollment completion expected Q1 2024, topline data Q2 2024.
- New Japanese patent for oral sulopenem bilayer tablet granted; expires no earlier than 2039.

## SEC filing metadata
- accession: 0000950170-23-041597
- form_type: 8-K
- ticker: ITRMF
- cik: 0001659323
- company_name: Iterum Therapeutics plc
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659323/000095017023041597/0000950170-23-041597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659323/000095017023041597/itrm-20230811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041597
- JSON: https://secwatch.observer/filing/0000950170-23-041597.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041597.txt

## Key facts
- Earnings Releases
  Iterum Therapeutics plc reported quarter ended June 30, 2023 results: net income $12.2 million.
  - Period: quarter ended June 30, 2023
  - Net income: $12.2 million
  - Result: reported results
  source text: Iterum Therapeutics plc issued a press release announcing its financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659323/000095017023041597/0000950170-23-041597-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.